TCR sequencing: applications in immuno-oncology research.

Immunooncol Technol · 2023 · PMC9996383 · PMID 36908996

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

showed a trendP value = 0.08so close (0.05 < p ≤ 0.1)

This showed a trend for increased maintenance of expanded pre-existing clones in responders ( P value = 0.08). 56 In other tumour types, Valpione et al. analysed pre-treatment biopsies from 20 patients with metastatic melanoma undergoing anti-PD-1 treatment. 57 They found higher TCR clonality pre-treatment in patients responding to ICB.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.